Why the study?
Does targeted arterial perfusion of verapamil and chemotherapeutic drugs improve tumor response in patients with advanced lung cancer?
Does targeted arterial perfusion of verapamil and chemotherapeutic drugs improve tumor response in patients with advanced lung cancer?
Targeted arterial perfusion of verapamil combined with chemotherapy achieved an 85% objective response rate in advanced lung cancer without inducing cardiac toxicity.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for targeted arterial perfusion of verapamil in advanced lung cancer; should not yet change practice.
PURPOSE: To assess the clinical efficacy of targeted arterial perfusion of verapamil and chemotherapeutic agents in the interventional therapy of lung cancer. METHODS: Forty patients with advanced lung cancer underwent treatment with targeted arterial perfusion of verapamil and chemotherapeutic agents using Seldinger technique. Interventional therapy was performed once a month, and each subject received interventional treatment for 2 or more cycles. The therapeutic efficacy was evaluated 2 months post-treatment. RESULTS: Out of 40 patients with advanced lung cancer, 5 cases achieved complete remission (CR) and 29 cases achieved partial remission (PR), with a total effectiveness (CR + PR) rate of 85 %. Besides, 32 cases achieved significantly alleviated clinical symptoms, and 29 cases had decreased clinical tumor stage. All subjects had stable karnofsky performance status score and body weight. Among the 40 patients, 13 cases had leucopenia, 10 cases had gastrointestinal reactions, 3 cases presented with elevated alanine aminotransferase/aspartate aminotransferase ratio, and 3 cases had fever. However, all these side effects relieved quickly. No elevation of BUN/Cr ratio and allergic reactions was observed. No significant changes in cardiac function and electrocardiogram were noticed after the treatment. CONCLUSIONS: Targeted arterial perfusion of verapamil and chemotherapeutic drugs can improve the clinical symptoms of patients with advanced lung cancer and increase the efficacy of chemotherapeutic agents, thereby providing an opportunity for radiotherapy or surgical treatment for advanced lung cancer.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: